Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival

We evaluated the association between germline genetic variants located within the 3′‐untranlsated region (polymorphic 3′UTR, ie, p3UTR) of candidate genes involved in multiple myeloma (MM). We performed a case‐control study within the International Multiple Myeloma rESEarch (IMMEnSE) consortium, consisting of 3056 MM patients and 1960 controls recruited from eight countries. We selected p3UTR of six genes known to act in different pathways relevant in MM pathogenesis, namely KRAS (rs12587 and rs7973623), VEGFA (rs10434), SPP1 (rs1126772), IRF4 (rs12211228) and IL10 (rs3024496). We found that IL10‐rs3024496 was associated with increased risk of developing MM and with a worse overall survival of MM patients. The variant allele was assayed in a vector expressing eGFP chimerized with the IL10 3′‐UTR and it was found functionally active following transfection in human myeloma cells. In this experiment, the A‐allele caused a lower expression of the reporter gene and this was also in agreement with the in vivo expression of mRNA measured in whole blood as reported in the GTEx portal. Overall, these data are suggestive of an effect of the IL10‐rs3024496 SNP on the regulation of IL10 mRNA expression and it could have clinical implications for better characterization of MM patients in terms of prognosis.

[1]  B. Nilsson,et al.  Genetic predisposition for multiple myeloma , 2020, Leukemia.

[2]  L. Yao,et al.  GOLGA7 rs11337, a Polymorphism at the MicroRNA Binding Site, Is Associated with Glioma Prognosis , 2019, Molecular therapy. Nucleic acids.

[3]  Gui-Ping Xu,et al.  The association between IGF1 Gene 3’-UTR polymorphisms and cancer risk , 2018, Medicine.

[4]  D. Campa,et al.  Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients , 2018, British journal of haematology.

[5]  C. Mayr Regulation by 3'-Untranslated Regions. , 2017, Annual review of genetics.

[6]  A. Allegra,et al.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma , 2017, Mediators of inflammation.

[7]  H. Goldschmidt,et al.  Identification of miRSNPs associated with the risk of multiple myeloma , 2017, International journal of cancer.

[8]  C. Dinarello,et al.  Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma , 2016, American journal of hematology.

[9]  D. Lin,et al.  A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer , 2016, Oncotarget.

[10]  Zhenli Gao,et al.  Effect of a functional polymorphism in the pre-miR-146a gene on the risk and prognosis of renal cell carcinoma. , 2015, Molecular medicine reports.

[11]  Yujiang Fang,et al.  The paradoxical role of IL-10 in immunity and cancer. , 2015, Cancer letters.

[12]  U. Vogel,et al.  Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. , 2015, Endocrine-related cancer.

[13]  W. Siffert,et al.  A 3′UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1 , 2014, Molecular Cancer.

[14]  D. Campa,et al.  Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case–control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium , 2012, Leukemia.

[15]  H. Goldschmidt,et al.  Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium , 2012, British journal of haematology.

[16]  V. Moreno,et al.  Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). , 2011, International journal of oncology.

[17]  E. Platz,et al.  Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer , 2009, Cancer Causes & Control.

[18]  W. Isaacs,et al.  Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.

[19]  Muin J. Khoury,et al.  Gene Prospector: An evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases , 2008, BMC Bioinformatics.

[20]  T. Therneau,et al.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. , 2008, Blood.

[21]  A. Dispenzieri,et al.  Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[23]  H. Goldschmidt,et al.  Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma , 2022 .

[24]  Jennifer L. Caswell-Jin,et al.  Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients , 2022 .